Suppression of Wnt/β-catenin signaling inhibits prostate cancer cell proliferation

European Journal of Pharmacology

Volumn 602, Issue 1, 2009, Pages 8-14

  Lu, Wenyan ^a   Tinsley, Heather N ^a,b   Keeton, Adam ^a   Qu, Zhican ^a   Piazza, Gary A ^a,b   Li, Yonghe ^a  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

catenin; NSAID; Prostate cancer; Small molecule inhibitor; Wnt signaling

Indexed keywords

ACETYLSALICYLIC ACID DERIVATIVE; ANTINEOPLASTIC AGENT; BETA CATENIN; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PKF 118310; SMALL MOLECULE INHIBITOR; SULINDAC SULFIDE; UNCLASSIFIED DRUG; WNT PROTEIN;

ARTICLE; CANCER CELL; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; DRUG INHIBITION; DRUG TARGETING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA; SIGNAL TRANSDUCTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BETA CATENIN; CELL PROLIFERATION; HUMANS; MALE; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TIME FACTORS; TUMOR CELLS, CULTURED; WNT PROTEINS;

EID: 57249108188     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.10.053     Document Type: Article

References (42)

1. Bafico A., Gazit A., Wu-Morgan S.S., Yaniv A., and Aaronson S.A. Characterization of Wnt-1 and Wnt-2 induced growth alterations and signaling pathways in NIH3T3 fibroblasts. Oncogene 16 (1998) 2819-2825
2. Bafico A., Liu G., Goldin L., Harris V., and Aaronson S.A. An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells. Cancer Cell 6 (2004) 497-506
3. Barker N., and Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat. Rev. Drug Discov. 5 (2006) 997-1014
4. Bierie B., Nozawa M., Renou J.P., Shillingford J.M., Morgan F., Oka T., Taketo M.M., Cardiff R.D., Miyoshi K., Wagner K.U., Robinson G.W., and Hennighausen L. Activation of β-catenin in prostate epithelium induces hyperplasias and squamous transdifferentiation. Oncogene 22 (2003) 3875-3887
5. Bruxvoort K.J., Charbonneau H.M., Giambernardi T.A., Goolsby J.C., Qian C.N., Zylstra C.R., Robinson D.R., Roy-Burman P., Shaw A.K., Buckner-Berghuis B.D., Sigler R.E., Resau J.H., Sullivan R., Bushman W., and Williams B.O. Inactivation of Apc in the mouse prostate causes prostate carcinoma. Cancer Res. 67 (2007) 2490-2496
6. Chen G., Shukeir N., Potti A., Sircar K., Aprikian A., Goltzman D., and Rabbani S.A. Up-regulation of Wnt-1 and β-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer 101 (2004) 1345-1356
7. Chesire D.R., Ewing C.M., Gage W.R., and Isaacs W.B. In vitro evidence for complex modes of nuclear β-catenin signaling during prostate growth and tumorigenesis. Oncogene 21 (2002) 2679-2694
8. de la Taille A., Rubin M.A., Chen M.W., Vacherot F., de Medina S.G., Burchardt M., Buttyan R., and Chopin D. β-Catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells. Clin. Cancer Res. 9 (2003) 1801-1807
9. Dihlmann S., and von Knebel Doeberitz M. Wnt/β-catenin-pathway as a molecular target for future anti-cancer therapeutics. Int. J. Cancer 113 (2005) 515-524
10. Goluboff E.T., Shabsigh A., and Saidi J.A. Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis. Urology 53 (1999) 440-444
11. Goluboff E.T., Prager D., and Rukstalis D. Safety and efficacy of exisulind in the treatment of recurrent prostate cancer following radical prostatectomy. J. Urol. 166 (2001) 882-886
12. Gounari F., Signoretti S., Bronson R., Klein L., Sellers W.R., Kum J., Siermann A., Taketo M.M., von Boehmer H., and Khazaie K. Stabilization of β-catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelium. Oncogene 21 (2002) 4099-4107
13. Gupta S., Adhami V.M., Subbarayan M., MacLennan G.T., Lewin J.S., Hafeli U.O., Fu P., and Mukhtar H. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res. 64 (2004) 3334-3343
14. Hall C.L., Bafico A., Dai J., Aaronson S.A., and Keller E.T. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res. 65 (2005) 7554-7560
15. Han A., Song Z., Tong C., Hu D., Bi X., Augenlicht L.H., and Yang W. Sulindac suppresses β-catenin expression in human cancer cells. Eur. J. Pharmacol. 583 (2008) 26-31
16. He X., Semenov M., Tamai K., and Zeng X. LDL receptor-related proteins 5 and 6 in Wnt/β-catenin signaling: arrows point the way. Development 131 (2004) 1663-1677
17. Horvath L.G., Henshall S.M., Lee C.S., Kench J.G., Golovsky D., Brenner P.C., O'Neill G.F., Kooner R., Stricker P.D., Grygiel J.J., and Sutherland R.L. Lower levels of nuclear β-catenin predict for a poorer prognosis in localized prostate cancer. Int. J. Cancer 113 (2005) 415-422
18. Jho E.H., Zhang T., Domon C., Joo C.K., Freund J.N., and Costantini F. Wnt/β-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol. Cell. Biol. 22 (2002) 1172-1183
19. Junior, J.P., Srougi, M., Borra, P.M., Dall' Oglio, M.F., Ribeiro-Filho, L.A., Leite, K.R., in press. E-cadherin and β-catenin loss of expression related to bone metastasis in prostate cancer. Appl. Immunohistochem. Mol. Morphol.
20. Kallakury B.V., Sheehan C.E., Winn-Deen E., Oliver J., Fisher H.A., Kaufman Jr. R.P., and Ross J.S. Decreased expression of catenins (α and β), p120 CTN, and E-cadherin cell adhesion proteins and E-cadherin gene promoter methylation in prostatic adenocarcinomas. Cancer 92 (2001) 2786-2795
21. Kashfi K., Ryan Y., Qiao L.L., Williams J.L., Chen J., Del Soldato P., Traganos F., and Rigas B. Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: evidence of a tissue type-independent effect. J. Pharmacol. Exp. Ther. 303 (2002) 1273-1282
22. Lepourcelet M., Chen Y.N., France D.S., Wang H., Crews P., Petersen F., Bruseo C., Wood A.W., and Shivdasani R.A. Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex. Cancer Cell 5 (2004) 91-102
23. Leung J.Y., Kolligs F.T., Wu R., Zhai Y., Kuick R., Hanash S., Cho K.R., and Fearon E.R. Activation of AXIN2 expression by β-catenin-T cell factor. A feedback repressor pathway regulating Wnt signaling. J. Biol. Chem. 277 (2002) 21657-21665
24. Liu G., Bafico A., Harris V.K., and Aaronson S.A. A novel mechanism for Wnt activation of canonical signaling through the LRP6 receptor. Mol. Cell. Biol. 23 (2003) 5825-5835
25. Lu W., Kim K.A., Liu J., Abo A., Feng X., Cao X., and Li Y. R-spondin1 Synergizes with Wnt3A in inducing osteoblast differentiation and osteoprotegerin expression. FEBS Lett. 582 (2008) 643-650
26. Lustig B., Jerchow B., Sachs M., Weiler S., Pietsch T., Karsten U., van de Wetering M., Clevers H., Schlag P.M., Birchmeier W., and Behrens J. Negative feedback loop of Wnt signaling through upregulation of conductin/axin2 in colorectal and liver tumors. Mol. Cell. Biol. 22 (2002) 1184-1193
27. Mi K., and Johnson G.V. Role of the intracellular domains of LRP5 and LRP6 in activating the Wnt canonical pathway. J. Cell. Biochem. 95 (2005) 328-338
28. Moon R.T., Kohn A.D., De Ferrari G.V., and Kaykas A. WNT and β-catenin signalling: diseases and therapies. Nat. Rev. Genet. 5 (2004) 691-701
29. Narayanan B.A., Narayanan N.K., Pittman B., and Reddy B.S. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. Clin. Cancer Res. 10 (2004) 7727-7737
30. Pruthi R.S., Derksen J.E., and Moore D. A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. BJU Int. 93 (2004) 275-278
31. Rigas B. The use of nitric oxide-donating nonsteroidal anti-inflammatory drugs in the chemoprevention of colorectal neoplasia. Curr. Opin. Gastroenterol. 23 (2007) 55-59
32. Saha B., Arase A., Imam S.S., Tsao-Wei D., Naritoku W.Y., Groshen S., Jones L.W., and Imam S.A. Overexpression of E-cadherin and β-catenin proteins in metastatic prostate cancer cells in bone. Prostate 68 (2008) 78-84
33. Shtutman M., Zhurinsky J., Simcha I., Albanese C., D'Amico M., Pestell R., and Ben-Ze'ev A. The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway. Proc. Natl. Acad. Sci. USA 96 (1999) 5522-5527
34. Song L.N., Herrell R., Byers S., Shah S., Wilson E.M., and Gelmann E.P. β-Catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcription. Mol. Cell. Biol. 23 (2003) 1674-1687
35. Steinbach G., Lynch P.M., Phillips R.K., Wallace M.H., Hawk E., Gordon G.B., Wakabayashi N., Saunders B., Shen Y., Fujimura T., Su L.K., and Levin B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342 (2000) 1946-1952
36. Tetsu O., and McCormick F. β-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 39 (1999) 422-426
37. Truica C.I., Byers S., and Gelmann E.P. β-Catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res. 60 (2000) 4709-4713
38. Verras M., and Sun Z. Roles and regulation of Wnt signaling and beta-catenin in prostate cancer. Cancer Lett. 237 (2006) 22-32
39. Verras M., Brown J., Li X., Nusse R., and Sun Z. Wnt3a growth factor induces androgen receptor-mediated transcription and enhances cell growth in human prostate cancer cells. Cancer Res. 64 (2004) 8860-8866
40. Whitaker H.C., Girling J., Warren A.Y., Leung H., Mills I.G., and Neal D.E. Alterations in β-catenin expression and localization in prostate cancer. Prostate 68 (2008) 1196-1205
41. Yan D., Wiesmann M., Rohan M., Chan V., Jefferson A.B., Guo L., Sakamoto D., Caothien R.H., Fuller J.H., Reinhard C., Garcia P.D., Randazzo F.M., Escobedo J., Fantl W.J., and Williams L.T. Elevated expression of axin2 and hnkd mRNA provides evidence that Wnt/β-catenin signaling is activated in human colon tumors. Proc. Natl. Acad. Sci. USA 98 (2001) 14973-14978
42. Yardy G.W., and Brewster S.F. Wnt signaling and prostate cancer. Prostate Cancer Prostatic Dis. 8 (2005) 119-126